強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Ankylosing Spondylitis Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Causes of Ankylosing Spondylitis
06.3 Pathophysiology
06.4 Epidemiology
06.5 Diagnosis
06.6 Treatment and Management
06.6.1 Analgesics
06.6.2 Corticosteroids
06.6.3 DMARDs
06.6.4 Biologics
06.6.5 Physiotherapy
06.6.6 Surgery
06.7 Economic Burden

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Mechanism of Action
08.1 TNF Inhibitors
08.2 COX Inhibitors
08.3 Others

09.Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Small Molecules

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11.Market Segmentation by Dosage Forms
11.1 Solid
11.2 Liquid

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of the Top Drugs for Ankylosing Spondylitis
20.2.2 Abbvie
20.2.3 Janssen Pharmaceuticals
20.2.4 Amgen
20.2.5 Pfizer
20.2.6 Merck
20.3 Other and Future Prominent Vendors

21.Pipeline Portfolio

22.Key Vendor Analysis
22.1 AbbVie Inc.
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation by Revenue 2013
22.1.4 Product Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Developments
22.1.8 SWOT Analysis
22.2 Amgen
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2013
22.2.4 Product Portfolio by Revenue 2013
22.2.5 Business Segmentation by Revenue 2012 and 2013
22.2.6 Geographical Segmentation by Revenue 2013
22.2.7 Business Strategy
22.2.8 Recent Developments
22.2.9 SWOT Analysis
22.3 Janssen Pharmaceuticals
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Recent Developments
22.3.4 SWOT Analysis
22.4 Merck
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.5 Pfizer
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue
22.5.6 Business Strategy
22.5.7 Key Developments
22.5.8 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Executive Summary of Global Ankylosing Spondylitis Market 2014-2019
Exhibit 3: Snapshot of Ankylosing Spondylitis
Exhibit 4: Diagnosis of Ankylosing Spondylitis
Exhibit 5: Treatment and Management of Ankylosing Spondylitis
Exhibit 6: Snapshot of the Economic Burden of Ankylosing Spondylitis
Exhibit 7: Snapshot of the Global Ankylosing Spondylitis Market
Exhibit 8: Global Ankylosing Spondylitis Market 2014-2019 (US$ million)
Exhibit 9: Drivers and Challenges of Global Ankylosing Spondylitis Market
Exhibit 10: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action
Exhibit 11: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action 2014
Exhibit 12: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule
Exhibit 13: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule 2014
Exhibit 14: Global Ankylosing Spondylitis Market Segmentation by Route of Administration
Exhibit 15: Global Ankylosing Spondylitis Market Segmentation by Route of Administration 2014
Exhibit 16: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms
Exhibit 17: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms 2014
Exhibit 18: Global Ankylosing Spondylitis Market by Geographical Segmentation 2014
Exhibit 19: Buying Criteria of the Global Ankylosing Spondylitis Market
Exhibit 20: Drivers and their Impact on the Key Customer Category of the Global Ankylosing Spondylitis Market
Exhibit 21: Drivers and Their Geography-wise Impact on the Global Ankylosing Spondylitis Market
Exhibit 22: YoY Sales Comparison of Top Drugs used for Ankylosing Spondylitis 2010-2013 (US$ million)
Exhibit 23: Revenue Share of the Top Drugs used for Ankylosing Spondylitis 2010-2013
Exhibit 24: Abbvie: Product Portfolio for Ankylosing Spondylitis
Exhibit 25: YoY Global Sales of Humira 2008-2013 (US$ million)
Exhibit 26: Janssen: Product Portfolio for Ankylosing Spondylitis
Exhibit 27: YoY Sales of Remicade 2005-2013 (US$ million)
Exhibit 28: YoY Sales of Simponi 2010-2013 (US$ million)
Exhibit 29: Amgen: Product Portfolio for Ankylosing Spondylitis
Exhibit 30: YoY Sales of Enbrel (In US and Canada) 2005-2013 (US$ million)
Exhibit 31: YoY Sales of Enbrel In US 2005-2013 (US$ million)
Exhibit 32: YoY Sales of Enbrel In Canada 2005-2013 (US$ million)
Exhibit 33: Region-wise Sales Comparison of Enbrel 2005-2013 (US$ million)
Exhibit 34: Pfizer: Product Portfolio for Ankylosing Spondylitis
Exhibit 35: YoY Sales of Enbrel (Outside US and Canada) 2009-2013 (US$ million)
Exhibit 36: YoY Sales of Enbrel (Outside US and Canada) 2008-2013 (US$ million)
Exhibit 37: Merck: Product Portfolio for Ankylosing Spondylitis
Exhibit 38: YoY Sales of Remicade 2005-2013 (US$ million)
Exhibit 39: YoY Sales of Simponi 2010-2013 (US$ million)
Exhibit 40: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 41: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 42: AbbVie Inc.: Sales by Geography 2013
Exhibit 43: Amgen: Business Segmentation by Revenue 2013
Exhibit 44: Amgen: Product Portfolio by Revenue 2013
Exhibit 45: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 46: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 47: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 48: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 49: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 50: Pfizer: Business Segmentation by Revenue 2013
Exhibit 51: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 52: Pfizer: Geographical Segmentation by Revenue 2013


【レポート販売概要】

■ タイトル:強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場2015-2019
■ 英文:Global Ankylosing Spondylitis Market 2015-2019
■ 発行日:2015年1月7日
■ 調査会社:Technavio
■ 商品コード:IRTNTR5050
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。